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Abstract: PURPOSE OF REVIEW: Obstructive sleep apnea (OSA) is heterogeneous in terms of con-
tributing pathophysiological mechanisms, clinical presentation, and consequences. Different study models
from animal models of intermittent hypoxia over case-control, cohort, and population-based observational
studies to uncontrolled interventional and randomized controlled interventional trials have contributed
to the knowledge base. Controversial findings on underlying mechanisms and consequences of untreated
OSA have challenged the field and resulted in uncertainty in treatment recommendations. RECENT
FINDINGS: The heterogeneity of OSA in pathogenesis and clinical outcomes and strengths and limita-
tions of different study models and designs used for studying OSA pathophysiology and cardiovascular
consequences are discussed on the background of controversial findings on cardiovascular outcomes in
OSA. In addition, recent findings from randomized controlled continuous positive airway pressure ther-
apy withdrawal trials, an efficient and controlled study model, are highlighted. SUMMARY: Novel designs
for clinical trials on long-term outcomes in the highly prevalent patient group with OSA addressing the
heterogeneity in underlying mechanisms, different phenotypes in terms of cardiovascular risk, and new
treatment concepts are needed to improve clinical practice standards.
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 CURRENTOPINION Cardiovascular consequences of obstructive sleep





Obstructive sleep apnea (OSA) is heterogeneous in terms of contributing pathophysiological mechanisms,
clinical presentation, and consequences. Different study models from animal models of intermittent hypoxia
over case-control, cohort, and population-based observational studies to uncontrolled interventional and
randomized controlled interventional trials have contributed to the knowledge base. Controversial findings
on underlying mechanisms and consequences of untreated OSA have challenged the field and resulted in
uncertainty in treatment recommendations.
Recent findings
The heterogeneity of OSA in pathogenesis and clinical outcomes and strengths and limitations of different
study models and designs used for studying OSA pathophysiology and cardiovascular consequences are
discussed on the background of controversial findings on cardiovascular outcomes in OSA. In addition,
recent findings from randomized controlled continuous positive airway pressure therapy withdrawal trials,
an efficient and controlled study model, are highlighted.
Summary
Novel designs for clinical trials on long-term outcomes in the highly prevalent patient group with OSA
addressing the heterogeneity in underlying mechanisms, different phenotypes in terms of cardiovascular
risk, and new treatment concepts are needed to improve clinical practice standards.
Keywords
continuous positive airway pressure, hypertension, intermittent hypoxia, obstructive sleep apnea, randomized
controlled trial
INTRODUCTION
The underlying mechanisms and pathophysiologi-
cal consequences of obstructive sleep apnea (OSA)
have been well described since its recognition as a
specific sleep-related breathing disorder in the
1970s. The cardiovascular consequences of OSA
were recognized early in the history of OSA [1],
yet there are still several uncertainties and contro-
versial findings in this field, especially on the effects
of treatment of OSA on cardiovascular outcomes.
The controversial findings might be explained by
having studied a heterogenous population with dif-
ferences in contributing pathomechanisms and
pathophysiological consequences of OSA and by
using different study designs and models. In addi-
tion, the difficulty in performing randomized con-
trolled continuous positive airway pressure (CPAP)
trials on long-term cardiovascular outcomes in both
symptomatic (unethical of withholding an effective
treatment) and asymptomatic patients (insufficient
treatment adherence, potentially not at risk for an
OSA-associated adverse cardiovascular outcome)
with OSA has challenged the field.
OSA is a heterogeneous disease not only
in symptom burden and cardiovascular and meta-
bolic consequences but also in the underlying
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pathophysiology. Contributing factors such as
upper airway anatomy and function, lung mechan-
ics, respiratory control, and arousal threshold
may vary considerably between individuals with
OSA. Characteristics like obesity or sex and comor-
bidities play an important role in both the patho-
genesis and sequelae of OSA, and are therefore
relevant for the clinical impact of OSA and treat-
ment recommendations. In addition, the metabolic
and cardiovascular consequences may differ consid-
erably between symptomatic and asymptomatic
patients with OSA, and between those with or
without a high hypoxic burden or pronounced
sleep fragmentation. The recent identification
of different phenotypes [2] and patient clusters
[3–5], and the development of treatment alterna-
tives to CPAP allow a more tailored treatment
approach and advance personalized medicine in
OSA as is the current concept in most chronic
respiratory diseases.
This highlights the need for novel study designs
using stratification by phenotypes, and the aware-
ness of the strengths and limitations of currently
used study models. The present review focuses on
current models and trial designs to study the vascu-
lar and other pathophysiological consequences of
OSA and treatment effects, and their limitations,
and outlines the lessons learned from the CPAP
withdrawal model, a specific study design to study
the sequelae of OSA in an efficient and controlled
way.
AVAILABLE APPROACHES TO STUDY THE
PATHOPHYSIOLOGY OF OBSTRUCTIVE
SLEEP APNEA – OF MICE AND HUMAN;
OF CASES, SNORERS AND CONTROLS;
OF OBSERVING AND RANDOMIZING; OF
INITIATING AND WITHDRAWING A
TREATMENT
The pathophysiological consequences of OSA have
been studied using different approaches – using cell
culture and rodent models of intermittent hypoxia,
simulated intermittent hypoxia in humans, case–
control studies comparing patients with OSA to
healthy controls and snorers, population-based epi-
demiological observational studies, cohort studies
of OSA, uncontrolled interventional trials, and ran-
domized controlled CPAP trials (Fig. 1). BecauseOSA
can be effectively treated with CPAP, studying treat-
ment effects provides knowledge on the reversible
consequences of OSA.
Intermittent hypoxia has been most extensively
studied as a direct pathophysiologicalmechanism in
OSA and is considered the most important factor
linking OSA with vascular damage. The effect of
arousals and intrathoracic pressure swings has been
studied as well [6–8]. Case–control and interven-
tional CPAP trials assessing OSA as a disease – rather
than looking at limited or simulated pathomechan-
isms of OSA – incorporate the risk of bias by con-
founding factors and pooling heterogenous patients
with distinct contribution of the direct pathome-
chanisms. Epidemiological observational studies
have generated hypotheses on cardiovascular con-
sequences of OSA, however, do not allow the iden-
tification of a causal relationship between OSA and
the observed changes in cross-sectional or longitu-
dinal analyses [9–15]. Each model and study design
has its benefits and limitations, and the current
knowledge on the consequences of OSA is based
on the combined evidence from experimental,
observational, and interventional studies.
Animal models of intermittent hypoxia
Rodent models of intermittent hypoxia have con-
tributed to the knowledge on pathophysiological
consequences of OSA, especially the alterations of
the cardiovascular system in chronic intermittent
hypoxia studied in the absence of confounders
[16,17]. Extent, duration and frequency of intermit-
tent hypoxia play a role in the balance between
maladaptive harm and adaptive beneficial mecha-
nisms (e.g. preconditioning effects). In addition, the
KEY POINTS
 Inconsistent findings on pathophysiological mechanisms
and long-term consequences of OSA have challenged
treatment concepts for patients with OSA.
 Different study models (cell culture and animal models
of intermittent hypoxia, case control studies, cohort
studies, populational-based observational studies,
uncontrolled interventional trials, randomized controlled
trials) have been used to study underlying mechanisms
and consequences of OSA, each design having its
advantages and limitations.
 Short-term CPAP withdrawal in previously highly
compliant patients is an effective way to study the
pathophysiological consequences of OSA and
differences between baseline and follow-up can be
attributed to OSA recurrence.
 OSA is a heterogeneous disease in terms of underlying
mechanisms, symptom burden, and
cardiovascular consequences.
 Addressing prognostically relevant phenotypes and
incorporating novel treatment options in well designed
trials will provide new knowledge to guide treatment
recommendations for patients with OSA.
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exact pattern of deoxygenation–reoxygenation and
the vessel type or target organ studied might deter-
mine the beneficial versus harmful effects of inter-
mittent hypoxia [18]. Experimental protocols and
hypoxia paradigms differ between different rodent
models and research groups [16,18], making com-
parison across studies and translating the findings to
humanOSAdifficult. However, these animalmodels
allow the identification of potential causality
between experimental intermittent hypoxia and
the outcome of interest. Important lessons on the
complex effects of intermittent hypoxia, for exam-
ple on increased sympathetic activity and blood
pressure [19,20], on endothelial dysfunction [21],
and on the role of adipose tissue for intermittent
hypoxia-associated insulin resistance [22] have been
learned from animal models.
The major limitations of these models are the
difficulty of comparing the degree and pattern of
exposure to experimental intermittent hypoxia to
human OSA, and the usually isolated assessment of
intermittent hypoxia excluding factors like poten-
tial hypercapnia, sleep fragmentation, intrathoracic
pressure swings, and hemodynamic effects, which
play an important role in the pathophysiological
consequences of OSA [23,24]. However, the isolated
assessment of intermittent hypoxia allows the better
understanding of the contribution of specific direct
mechanisms to intermediate consequences and
vascular damage in OSA, which is important for
identification of at-risk groups and for mecha-
nism-targeted treatment.
Clinical trials including patients with
obstructive sleep apnea
In patients with OSA, the way from case–control
and cohort studies over uncontrolled interventional
trials to randomized controlled CPAP trials and
meta-analyses has led from hypothesis generating
to establishing evidence for a causal relationship
between OSA and hypertension.
Case–control studies comparing patients with
OSA to snorers without OSA and/or healthy controls
have suggested a high prevalence of hypertension in
OSA and identified patient characteristics like male
sex that strengthen this association [25,26]. How-
ever, case–control studies have important limita-
tions (e.g. selection bias) that limit their validity.
Population-based observational studies such as
theWisconsin Sleep Cohort Study or the Sleep Heart
Health Study have made important contributions to
the knowledge on the cardiovascular consequences
of OSA. In a longitudinal analysis, there was a dose–
response relationship between OSA severity and
incident hypertension at a follow-up of 4 years
[27]. A cross-sectional analysis of the largest popu-
lation-based study on this topic confirmed a strong
FIGURE 1. Different study models and design previously used to study pathophysiology and cardiovascular consequences of
obstructive sleep apnea.
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association of OSA with hypertension in the sub-
groupwith severe OSA only [9]. In addition, OSA has
been associated with adverse cardiovascular out-
come in population-based cohort and observational
sleep clinic cohort studies [13,28–33]. These studies
have indicated that the risk for cerebrovascular and
cardiovascular events might only be elevated in
moderate-to-severe or severe OSA but not in mild
OSA. However, the association between OSA and
cardiovascular disease is multifactorial and medi-
ated by comorbidities and the typical clustering of
cardiovascular risk factors in these patients, which
are important confounders. Randomized controlled
CPAP trials on cardiovascular outcomes are difficult
to perform for several reasons, for example because
of the problem of withholding an effective treat-
ment to symptomatic patients over a prolonged
period, selecting a population potentially not at risk
for adverse outcome when including only asymp-
tomatic patients, and the difficulty of achieving a
sufficient treatment adherence to CPAP. If CPAP
adherence is insufficient, the treatment effect is
underestimated or completely vanishes. Ideally,
patients use their CPAP every night for the whole
night (6–8h). However, nightly CPAP usage in pre-
vious large randomized controlled trials was typi-
cally 3–4h with rare exceptions between 4 and 5h
[34–41].
Up to now there is only one published random-
ized controlled trial that has been powered to assess
the effect of CPAP therapy on hard cardiovascular
endpoints [35]. This trial has been well designed
considering existing evidence for sample size esti-
mation, trying to increase adherence by using a run-
in CPAP period, and responsibility by excluding
severely symptomatic patients but using sleepiness
in minimization for random allocation to CPAP or
usual care. This trial in middle-aged predominantly
male Asians with established cardiovascular or cere-
brovascular disease in not severely symptomatic
patients with OSA (oxygen desaturation index 28/
h in a level IV home sleep study, Epworth Sleepiness
Scale 7.4) found no effect of CPAP therapy (mean
usage 3.3h/night) on secondary prevention of vas-
cular death or hospitalization [35].
Other randomized controlled trials provided
clear evidence for an independent association of
OSA with hypertension and with endothelial dys-
function [42–44]. Considering all evidence from
randomized controlled trials independent of the
patient group studied, the blood pressure measure
used, or treatment adherence, the overall blood
pressure lowering effect of CPAP therapy is 2–3
mmHg. However, the effect size differs between
blood pressure measures (mean 24-h-blood pressure
vs night-time blood pressure versus office blood
pressure versus home blood pressure) and between
patient groups (no hypertension vs. hypertension
versus resistant hypertension; sleepy vs. nonsleepy
OSA; nonsevere vs. severe OSA). In addition, meta-
analyses have also provided evidence for a signifi-
cant association of the blood pressure lowering
effect of CPAP and nightly CPAP usage [45]. In
patients with resistant hypertension, the effect of
CPAP on blood pressure was more than double (5–7
mmHg) compared with patients without resistant
hypertension [46,47]. There is still a need for well
designed randomized controlled trials in the
research field of OSA to assess outcomes in different
phenotypes and to evaluate treatment alternatives
to CPAP. However, the time for classical randomized
controlled trials simply randomizing everybody to
the treatment or the control group seems to be over.
Because of feasibility issues and the lessons we have
learned from previous trials, such a trial design is
unlikely to provide robust findings that influence
clinical practice. Phenotyping and stratification and
novel treatment concepts should be considered
when designing future trials. In addition, if novel
therapeutic devices are used, identification of
responder and nonresponder criteria should be
implemented into the trial design.
THE CONTINUOUS POSITIVE AIRWAY
PRESSURE WITHDRAWAL MODEL TO
STUDY THE PATHOPHYSIOLOGY OF
OBSTRUCTIVE SLEEP APNEA
To overcome some of the problems of conventional
CPAP trials and to propose and efficient model to
study the pathophysiological consequences in a
controlled way, the CPAP withdrawal model was
introduced [42]. The CPAP withdrawal model is
an experimental protocol to investigate the patho-
physiology of human OSA and to assess treatment
effects of CPAP or novel therapeutic devices [48].
In a randomized controlled interventional trial
design, patients with knownOSAwho are effectively
treated (residual AHI<5/h) and optimally adherent
to CPAP (using it every night and all night) are
randomized to either continue therapeutic CPAP
(control group) or to withdraw it by the use of a
subtherapeutic sham-device (intervention group)
for a short period (Fig. 2). Inmost patients, a therapy
withdrawal of several days results in recurrence of
OSA and therefore allows studying the pathophysi-
ological changes that can be attributed to OSA in a
controlled model, avoiding many sources of bias of
case–control studies or conventional CPAP-trials.
Persistence and immediate recurrence of OSA is
confirmed before study inclusion by home over-
night pulse-oximetries off CPAP. After a minimum
Cardiovascular consequences of obstructive sleep apnea Schwarz
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of 2 weeks being back on CPAP, patients have their
baseline sleep study on CPAP and baseline assess-
ments while being treated for OSA. The next morn-
ing, patients are randomized to the control or the
withdrawal group and perform a nightly home
oximetry during the intervention period that docu-
ments the recurrence pattern of OSA. The follow-up
sleep study and assessments are performed 2 weeks
after randomization on the allocated treatment
(Fig. 2). Each patient in the withdrawal group serves
as its own control at baseline, and the control group
continuing therapeutic CPAP helps to avoid the
typical bias of nonrandomized studies. Several of
these randomized controlled CPAP withdrawal
trials have been performed in the last years and gave
insight into cardiovascular and metabolic conse-
quences of OSA and recurrence patterns in response







,57]. The model has also been used to assess
the effect of other treatments than CPAP [58,59
&&
].
In addition, important lessons on night-to-night
variability and sustained effects of OSA treatment
have been learned [49,53
&
].
Knowledge gained from continuous positive
airway pressure withdrawal studies
These randomized controlled CPAP withdrawal
trials have provided robust evidence on diverse
cardiovascular and metabolic consequences of OSA
[48]. Recurrence of OSA during a short-term CPAP
therapy withdrawal was associated with a significant
increase in urinary catecholamine as marker of
increased sympathetic activity and a progressive
decrease in peripheral endothelial function after 1
and 2 weeks when compared to the control group
continuing CPAP [42,60]. Along with these changes,
a clinically relevant increase in morning home and
office systolic (þ9 and þ5 mmHg, respectively) and
diastolic blood pressure (þ7 and þ5 mmHg, respec-
tively) was found [43]. The observed change in blood
pressure in untreated OSA in this group of patients
with an optimal CPAP adherence was considerably
larger than in conventional CPAP trials, in which
CPAP usage is usually suboptimal and the treatment
effect underestimated. A higher AHI, the use of more
antihypertensive drugs, a lower blood pressure at
baseline and the absence of statin usage were inde-
pendentpredictorsof apronounced increase inblood
pressure in response to CPAP withdrawal. This high-
lights the role of OSA as a secondary cause of hyper-
tension and the need for a combined treatment by
antihypertensive drugs and CPAP in hypertensive
patients with OSA. The findings led also to the spec-
ulation of a protective role of statins in OSA-induced
endothelial dysfunction.
The heart and the brain are important target
organs potentially being affected by the detrimental
FIGURE 2. The CPAP therapy withdrawal model as it is used in randomized sham-controlled CPAP trials or with additional
treatment arms to test a novel therapeutic device.
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pathophysiological sequelae of OSA. In a random-
ized controlled CPAP withdrawal trial powered to
detect a minimal clinically important difference in
myocardial perfusion as assessed by the gold stan-
dard technique N13-ammonia-positron emission
tomography, OSA recurrence had no effect on myo-
cardial perfusion and coronary endothelial function
during daytime in patients with moderate or severe
OSA despite a relevant increase in blood pressure
and heart rate and the previously found peripheral
endothelial dysfunction [51]. In line with the find-
ings on myocardial perfusion, an additional ran-
domized controlled trial studying cerebrovascular
reactivity using functional magnetic resonance
imaging measuring blood oxygen level-dependent
response to breathing stimuli during daytime found
no effect of OSA on cerebrovascular reactivity or
cerebral blood flow [56
&
]. However, despite pre-
served vascular function during daytime, the brain
is exposed to OSA-induced changes during sleep
that might explain neurocognitive dysfunction.
Near infrared spectroscopy was used to monitor
cerebral tissue oxygenation and hemoglobin con-
centration during in-hospital sleep studies in
patients with moderate to severe OSA who were
allocated to either withdraw CPAP or continue ther-
apeutic CPAP [55
&&
]. OSA recurrence was associated
with intermittent and sustained falls in cerebral
tissue oxygenation during sleep of a clinically
relevant degree, in some patients sufficient to
cause cerebral ischemia associated with functional
impairment.
Using the CPAP withdrawal model as human
model of intermittent hypoxia, markers of oxidative
stress were assessed in 59 patients with moderate or
severe OSA at baseline and 2 weeks after randomi-
zation to either therapeutic or subtherapeutic CPAP.
Contrary to the hypothesis, the return of intermit-
tent hypoxia during CPAP withdrawal did not result
in increased levels of markers of oxidative stress, for
example early morning blood malondialdehyde
[50]. OSA recurrence led to a significant reduction
in urinary F2-isoprostane suggesting a reduction in
oxidative stress. A possible explanation was a signif-
icant increase in the antioxidant superoxide dismut-
ase, a marker of hypoxic preconditioning, that
might prevent the damage of hypoxia-reoxygena-
tion in intermittent hypoxia.
A recent randomized controlled cross-over trial
studied the role of intermittent hypoxia onmorning
blood pressure by withdrawing both study arms
from CPAP and randomizing them to either noctur-
nal supplemental oxygen or sham-oxygen (air)
[59
&&
]. In this study design, a short-term CPAP with-
drawal has been used as real-life model of intermit-
tent hypoxia in OSA. Nocturnal supplemental
oxygen abolished the rise in early morning blood
pressure during CPAP withdrawal when compared
to sham-oxygen. As supplemental oxygen attenu-
ated the hypoxic dips without significantly affecting
the apneahypopnea index or arousals, it was con-
cluded that intermittent hypoxia is the dominant
mechanism for the rise in morning blood pressure
(and sympathetic activity) seen in patients withOSA
[59
&&
]. This randomized controlled trial provides
firm evidence for the mechanistic pathway ‘inter-
mittent hypoxia-sympathetic overshoot-increased
blood pressure‘.
The CPAP withdrawal model has also been used
for a metabolomic study in OSA. Untargeted
exhaled breath analysis was used to define the effect
of OSA on the breath profile, which contains a
wealth of metabolic information as volatile exhaled
compounds that are released along the blood gas
barrier. This study has shown that OSA is associated
with a distinct breath pattern allowing differentia-
tion between treated and untreated OSA with a high
diagnostic accuracy [52]. OSA recurrence resulted in
an increase in exhaled molecules associated with
stress, altered lipid peroxidation and the gut flora
metabolism [52].
Although a recurrence of OSA to some degree is
typically seen in the majority of patients from the
first nights on when CPAP is stopped – although
usually of a lower severity compared to the time of
the diagnosis, we found that about a third of an
efficiently CPAP-treated OSA cohort does not expe-
rience a recurrence of OSA within four nights off
CPAP withdrawal (during the pretrial screening
[49]). This finding was not explained by a change
in weight. These differences in recurrence may
reflect different OSA phenotypes and indicate sus-
tained effects of CPAP therapy. The underlying
mechanisms remained speculative in this study.
Upper airway function and edema and respiratory
control are possible factors being influenced by
long-standing CPAP therapy. Understanding why
and how some have an immediate return of OSA
and some have not will help to develop novel treat-
ment strategies for patents with suboptimal and
intermittent CPAP usage.
Nightly oximetry during the 2-week CPAP with-
drawal revealed a high night-to-night variability of
OSA severity according to the oxygen desaturation
index (Fig. 3) inmost patients. Shifts in OSA severity
category between nights were found in 78% of
patients. The variability was higher in less severe
OSA [53
&
]. This knowledge challenges the current
practice of a single-night diagnostic sleep study and
therapeutic recommendations based on conven-
tional thresholds of apneas and hypopneas or cyclic
oxygen desaturations per hour of sleep.
Cardiovascular consequences of obstructive sleep apnea Schwarz
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Its advantages and its limitations
The withdrawal model allows fast recruitment
of well characterized patients and a limited inter-
vention period, and estimation of a maximal treat-
ment or withdrawal effect. Themodel avoids many
sources of bias (e.g. by randomization, maximal
treatment effect, no change of confounders like
obesity in the short-term). However, the with-
drawal model might also have a bias towards
including patients with less severe OSA-related
symptoms because they are more likely to tempo-
rarily stop CPAP. A major limitation is that the
consequences of OSA recurrence during a short-
term withdrawal of CPAP therapy might not nec-
essarily be identical with long-term effects of
untreated OSA.
IMPLICATIONS FOR FUTURE RESEARCH
AND FUTURE TARGETS
It is unknown to which extent the changes observed
in response to OSA recurrence during a 2-week CPAP
therapy withdrawal can be translated to long-term
consequences of OSA, and which adaptive mecha-
nisms will be activated in the long term. Therefore, a
planned study will use an adapted study design to
allow comparison of pretreatment, changes upon
CPAP therapy and withdrawal effects to compare
acute, intermediate and chronic consequences of
OSA on cardiovascular and metabolic outcomes.
In other future randomized controlled CPAP with-
drawal trials, the effect of OSA on the control of
comorbidities, e.g. heart failure, will be assessed
and novel therapeutic approaches tested in a
head-to-head comparison with both CPAP and
untreated OSA.
CONCLUSION
In summary, there are many different study models
anddesigns available to study thepathophysiological
consequencesofOSA.Eachmodelhas itsbenefits and
its limitations. TheCPAPwithdrawalmodel allows to
study OSA pathophysiology and treatment alterna-
tives to CPAP in a controlled way but has a limited
comparability to long-term treatment effects of
CPAP. Combining the strengths of different models
in collaboration projects addressing the current
needs and uncertainties in the field of OSA, using
novel statistical approaches, and incorporating
emerging alternative treatments to CPAP for specific
subgroupswill keep this fieldof research challenging.
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